{"id":"W2257109151","doi":"10.1200/jco.2008.26.15_suppl.1026","title":"Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Rash; Internal medicine; Clinical endpoint; Mucositis; Gastroenterology; Metastatic breast cancer; Phases of clinical research; Nausea; Oncology; Cancer; Clinical trial; Breast cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002103904,0.001508156,0.001648678,0.0003324711,0.0003261089,0.0006757688,0.0005415538,0.0009228205,0.003229491],"category_scores_gemma":[0.001317751,0.0004473461,0.001321419,0.0003605871,0.0007459454,0.0006606221,0.0003228324,0.002134752,0.0004727296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000814154,"about_ca_system_score_gemma":0.001333862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006845252,"about_ca_topic_score_gemma":0.001543319,"domain_scores_codex":[0.9995628,0.0002488715,0.00002931313,0.00005379539,0.00003264187,0.00007257749],"domain_scores_gemma":[0.9990938,0.0002006062,0.0001400655,0.00004719069,0.00004037608,0.0004779481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9053059,0.02647943,0.005326621,0.0004044291,0.001024886,0.0002081118,0.0001786711,0.001604697,0.01308479,0.0001238588,0.001469488,0.04478905],"study_design_scores_gemma":[0.6347618,0.3488712,0.01241101,0.00002196625,0.0004915512,0.0001997784,0.00003265486,0.0006464829,0.00116765,0.00009903398,0.001280908,0.00001603457],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957461,0.001106222,0.0002190755,0.0002846673,0.00007357415,0.0009820103,0.0004311777,0.0000364793,0.001120721],"genre_scores_gemma":[0.9930612,0.001119874,0.0009041238,0.0003671771,0.0001842179,0.001112606,0.001870454,0.00001148296,0.001368807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003229491,"threshold_uncertainty_score":0.0111267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1342789399803358,"score_gpt":0.4944826051640951,"score_spread":0.3602036651837593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}